Researchers develop novel treatment to prevent graft-versus-host-disease

January 11, 2017
New research reveals that targeting two distinct cell signaling pathways required for T cell activity could potentially be used to prevent undesirable post-stem cell transplant reactions without compromising tumor-killing function in cancer patients. Credit: Chris Bickel / Science Translational Medicine (2017)

Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants. In a new study published as the cover story in Science Translational Medicine, Moffitt Cancer Center researchers show that a novel treatment can effectively inhibit the development of GVHD in mice and maintain the infection- and tumor-fighting capabilities of the immune system.

Stem can be used to treat patients who have certain types of cancer, such as leukemia or lymphoma. Many patients who have stem cell transplants receive an allogeneic transplant - donated by another person. One risk associated with allogeneic is GVHD during which the donated immune cells fail to recognize the patient's own tissues and organs. The symptoms of GVHD vary and can be life-threatening. Common symptoms include rash, nausea and vomiting, diarrhea, and occasionally jaundice and liver failure.

In order to reduce the risk of GVHD, physicians try to match the recipient and donor tissue types as close as possible and prophylactic medicine is given throughout the transplant process. However, patients may still develop GVHD. The medications used to prevent GVHD are not very selective and suppress the activity of many different immune cell types; good and bad. As a result, GVHD prevention can increase the risk of serious infections and also inhibit the ability of donor immune cells from fighting against residual leukemia or lymphoma cells.

A team of Moffitt researchers led by Brian C. Betts, M.D., are trying to develop better, more effective treatments for preventing GVHD. Their goal is to develop drugs that can block those components of the immune system that contribute to GVHD, but do not affect the components of the that are important for fighting infections and the tumor cells.

"It is known that Aurora kinase A and JAK2 pathway activation contributes to GVHD. However, drugs that inhibit either protein alone do not completely prevent GVHD," said Betts. "We hypothesized that co-treatment with drugs that target both Aurora kinase A and JAK2 could prevent GVHD better than either drug alone."

The researchers discovered that combined inhibition of Aurora kinase A and JAK2 promotes the differentiation of potent regulatory T cells, specialized immune cells that prevent GVHD. Aurora kinase A and JAK2 also significantly reduced GVHD in mice and allowed for the development of anti-cancer . This was best demonstrated by a drug developed at Moffitt that inhibits both Aurora kinase A and JAK2 simultaneously, eliminating the need to use two different medications.

"This novel prevention strategy warrants further investigation because of its potential to reduce the risk of GVHD and possibly be more effective and selective than commonly used GVHD treatments currently available today," added Betts.

Explore further: Immune cell subset is associated with development of gastrointestinal GVHD after HSCT

More information: "Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function," Science Translational Medicine, stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aai8269

Related Stories

Recommended for you

Potential new treatment for kidney failure in cancer patients

April 25, 2017

Kidney dysfunction is a frequent complication affecting more than 50 percent of all cancer patients, and is directly linked to poor survival. Despite the high occurrence, it is still not clear how presence of a tumour contributes ...

Patients with drug-resistant malaria cured by plant therapy

April 24, 2017

When the standard malaria medications failed to help 18 critically ill patients, the attending physician in a Congo clinic acted under the "compassionate use" doctrine and prescribed a not-yet-approved malaria therapy made ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.